SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$13.09
+1.47%Year over year
Reported trailing growth
- Revenue
- +222.3%
- EBITDA
- +57.9%
- EBIT
- +42.7%
- EPS
- +35.4%
- Free cash flow
- +27.0%
- Operating cash flow
- +27.1%
Forward estimates
Based on analyst estimates
- Revenue
- +24.7%
- EBITDA
- +121.5%
- EPS
- +67.0%
Three-year CAGR
- Revenue
- +627.8%
- EBITDA
- +19.8%
- EBIT
- +19.6%
- Net income
- +10.5%
- EPS
- +11.8%
- Free cash flow
- -17.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026